Livia Stanger and Colleagues Link CS014 to in Vivo Thrombosis
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
CS014, a novel HDAC inhibitor, prevents blood clots as effectively as valproic acid but without hepatotoxic metabolites, offering safer antithrombotic therapy without increasing bleeding risk.”
Read the full article here.
Article: Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
Authors: Livia Stanger, Pooja Yalavarthi, Reheman Adili, Devin Gilmore, Timothy Hoang, Avery Campbell, Paul Krenik, David Gustafsson, Jan Fryklund, Tomas Fex, Nicholas Oakes, Jonas Faijerson Säljö, Björn Dahlöf, Joan Beckman, Michael Holinstat
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 28, 2026, 13:55Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD
-
Jan 28, 2026, 13:35Louise St Germain Bannon Invites You to Submit Your Work to JTH and RPTH
-
Jan 28, 2026, 13:14Robert Campbell Congratulates Izabella Andrianova for Her Recent Publication in JTH
-
Jan 28, 2026, 12:59Pall Onundarson: Diluted Fiix Test Can Be Used to Measure DOACs
-
Jan 28, 2026, 12:06Gevorg Tamamyan On Transparency as the Foundation of Trust
-
Jan 28, 2026, 11:54Abdulrahman Katib on STORM-PE Results In Favour of Thrombectomy in PE
-
Jan 28, 2026, 11:45Eslam Elkhadrawy on Heparin-Induced Thrombocytopenia
-
Jan 28, 2026, 11:38Arun V J: Why Does Only 3% Donate Blood Even Though 95% Believe Donating Is Essential?
-
Jan 28, 2026, 08:59Chris Jones: Quality Over Quantity is Definitely The Priority